Tilray (TLRY) is set to report Q4 earnings with consensus EPS of $0.21 and revenue of $246.3M, up 9.7% YoY. Analysts highlight strong international growth (~73% YoY in Q3) and the HelloMD acquisition for vertical integration. Investors will focus on whether international momentum continues, potential US market entry upon rescheduling, and updates on fiscal 2026 EBITDA guidance ($62M-$72M). Roth Capital recently upgraded the stock to Buy.